Emurea25%

Emurea is a high-strength topical keratolytic and emollient preparation used for skin conditions involving excessive dryness, thickening, or scaling.

Established/labeled uses

• Xerosis (severe dry skin) and ichthyosis
• Hyperkeratotic conditions such as calluses, corns, and thickened, rough or scaling skin patches
• Keratosis pilaris and dry, hyperkeratotic eczema/dermatitis
• Softening and debridement of hyperkeratotic tissue prior to other topical therapy (e.g., before topical corticosteroids in thickened plaques)

Adjunct/off-label use (commonly practiced)

• Adjunctive softening of thickened, scaly plaques in chronic plaque psoriasis (used together with, not instead of, disease-directed therapy)
• Diabetic dry-skin care as part of a foot-care regimen (used under medical supervision because of impaired healing risk)

Emurea is for external use on intact, non-infected skin only; it is not a treatment for any underlying systemic disease.

Each pack of Urea [25%] contains Urea 25% w/w as the active ingredient in a suitable emollient cream/ointment base.

Emurea is a topical dermatological preparation containing urea at a 25% concentration, a strength that provides pronounced keratolytic (skin-softening/exfoliating) action in addition to the moisturizing (humectant) effect seen at lower urea concentrations.

It works by helping the outer skin layer (stratum corneum) hold more water and by loosening the bonds between hardened, dead skin cells, so that thickened, dry, rough or scaling skin becomes softer and easier to shed.

Topical keratolytic and emollient agent — Emurea belongs to the dermatological preparations used for hyperkeratotic and dry-skin conditions.

Urea [25%] acts through two complementary mechanisms:

• Humectant/hydrating effect: urea binds water within the stratum corneum, increasing its water-holding capacity and reducing transepidermal water loss.
• Keratolytic effect: at concentrations of about 20% and above, urea disrupts hydrogen bonding within keratin, softening intercellular cement and promoting shedding (desquamation) of hyperkeratotic, thickened skin.

Systemic absorption of topical urea through intact skin is minimal, so systemic pharmacologic effects are not expected with normal use of Urea [25%].

For external (topical) use only. Clean and dry the affected area, then gently massage a thin layer of Emurea into the skin until absorbed. Avoid contact with the eyes, lips, and other mucous membranes. Wash hands after application unless the hands are the treated area. Do not bandage or occlude the area unless specifically instructed by a physician.

No clinically significant systemic drug interactions have been well established for Emurea because systemic absorption through intact skin is minimal.

• Other topical products: because urea acts as a penetration enhancer, applying Emurea together with or immediately before other topical medicines may increase local absorption of those products; use combinations only on medical advice.
• Other keratolytic/exfoliating agents (e.g., salicylic acid, alpha-hydroxy acids): concurrent use with Emurea may increase local skin irritation.

Emurea is generally well tolerated. Reported side effects are mostly local skin reactions:

• Transient stinging or burning sensation on application, especially on broken, fissured, or previously irritated skin
• Redness, itching, or mild irritation at the application site
• Dryness or peeling of the skin
• Allergic contact dermatitis (uncommon)

Discontinue Emurea and seek medical advice if excessive irritation, rash, or signs of an allergic reaction occur.

There are no well-controlled studies of topical Emurea in pregnant or breastfeeding women. Because systemic absorption through intact skin is minimal, the risk from appropriate topical use is expected to be low; however, Emurea should be used during pregnancy and lactation only if clearly needed and only over limited body areas, and a physician should be consulted before use.

If used while breastfeeding, avoid application to the breast/nipple area to prevent inadvertent ingestion by the infant.

• Emurea is for external use only; do not swallow.
• Avoid contact with the eyes, lips, and mucous membranes; rinse thoroughly with water if accidental contact occurs.
• A transient stinging or burning sensation may occur on application, particularly on broken or fissured skin.
• Do not apply Emurea to open wounds or actively infected skin without medical guidance.
• Apply only to the affected area(s) as directed; avoid use on large areas of skin unless instructed by a physician.
• Discontinue use and consult a physician if excessive irritation, redness, or worsening of the skin condition occurs.
• Keep out of reach of children.

Topical overdose with Emurea is unlikely to cause serious systemic effects because absorption through intact skin is minimal, but excessive or prolonged application may worsen local skin irritation.

If Emurea is accidentally swallowed, or if signs of a severe reaction occur after use, seek immediate medical attention or contact a poison control center; do not attempt specific home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep the container tightly closed. Keep out of reach of children.

Renal/hepatic impairment: no dose adjustment is expected to be necessary for topical Emurea because systemic absorption is minimal; specific studies are lacking.

Pediatric patients: safety and efficacy of Emurea have not been formally established in infants and young children; use only under medical supervision and on limited areas.

Elderly patients: Emurea is commonly used for age-related dry skin (xerosis) in elderly patients and is generally well tolerated; monitor for skin irritation.

Pregnancy and lactation: see Pregnancy and lactation section above.

Emurea may be used for as long as needed to manage chronic dry, thickened, or scaling skin, and treatment can typically be continued or repeated as required. If there is no improvement within 2 to 4 weeks, or if the condition worsens, a physician should be consulted to reassess the diagnosis and treatment plan.

Keratolytics; Emollients/humectants; Topical dermatological preparations

Urea [25%] hydrates the skin by binding water in the stratum corneum (humectant action) and, at its 25% concentration, breaks hydrogen bonds within keratin to loosen and soften hyperkeratotic tissue (keratolytic action), promoting shedding of thickened, dry, or scaling skin.

Safety and efficacy of Emurea have not been formally established in infants and young children. If use in a child is considered necessary, it should be limited to small affected areas, used for the shortest effective duration, and only under the guidance of a physician, since children have a higher skin-surface-to-body-weight ratio and may be more susceptible to local irritation.